News on sequencing-based testing, NGS gene panels, & diagnostic exomes in genetics, genomics, and molecular diagnostics.
The firm said it will offer 4.5 million shares of its common stock at $20 per share. It expects to close its follow-on public offering on July 16.
OrigiMed is a Shanghai, China-based company focusing on the development of new oncology assays.
The researchers developed a protocol for dengue and chikungunya virus detection, which they plan to continue to test for outbreak monitoring and diagnostics.
The molecular diagnostics company previously raised $180 million in its 2015 initial public offering.
An analysis has found that the odds of getting a diagnosis through WES or WGS is 8.3 times greater than it is through chromosomal microarrays.
